Free Trial

NexImmune (NEXI) Stock Price, News & Analysis

-0.01 (-0.35%)
(As of 12:29 PM ET)
Today's Range
50-Day Range
52-Week Range
248 shs
Average Volume
1.22 million shs
Market Capitalization
$3.95 million
P/E Ratio
Dividend Yield
Price Target
NEXI stock logo

About NexImmune Stock (NASDAQ:NEXI)

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NEXI Stock Price History

NEXI Stock News Headlines

NexImmune (NASDAQ:NEXI) Shares Up 1.3%
NexImmune slips after securities offering
NexImmune, Inc. Common Stock (NEXI)
Why Is NexImmune (NEXI) Stock Up 353% Today?
NexImmune Inc Ordinary Shares NEXI
See More Headlines
Receive NEXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$3.32 per share


Free Float
Market Cap
$3.95 million
Not Optionable
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Kristi Jones R.Ph. (Age 61)
    CEO, President & Director
    Comp: $989.28k
  • Dr. Mathias Oelke Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $605.78k
  • Mr. John Trainer M.B.A. (Age 50)
    Comp: $1.33M
  • Mr. Albert Nicholas Marchio II (Age 72)
    Interim CFO & Principal Accounting Officer
  • Mr. Karen Haslbeck
    Head of Human Resources
  • Dr. Daniel P. Bednarik
    Senior Vice President of Molecular Engineering & Protein Design
  • Dr. Robert Douglas Knight M.D. (Age 73)
    Chief Medical Officer
    Comp: $454.77k
  • Mr. Chad Rubin
    Senior Vice President of Corporate Affairs
  • Dr. Jack A. Ragheb M.D.
    Ph.D., Senior Vice President of Translational Science
  • Mr. Matthew Schiller
    Head of Business Development

NEXI Stock Analysis - Frequently Asked Questions

How have NEXI shares performed in 2024?

NexImmune's stock was trading at $2.22 at the start of the year. Since then, NEXI shares have increased by 29.7% and is now trading at $2.88.
View the best growth stocks for 2024 here

When is NexImmune's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our NEXI earnings forecast

How were NexImmune's earnings last quarter?

NexImmune, Inc. (NASDAQ:NEXI) posted its quarterly earnings results on Monday, May, 20th. The company reported ($2.21) earnings per share (EPS) for the quarter.

When did NexImmune's stock split?

NexImmune's stock reverse split before market open on Thursday, October 19th 2023. The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did NexImmune IPO?

NexImmune (NEXI) raised $75 million in an initial public offering on Friday, February 12th 2021. The company issued 4,700,000 shares at $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. served as the underwriters for the IPO.

How do I buy shares of NexImmune?

Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NEXI) was last updated on 6/13/2024 by Staff

From Our Partners